A Phase 2/3 interventional study of Elamipretide and Placebo in Barth Syndrome, sponsored by Stealth BioTherapeutics Inc.. Completed at 1 site in United States. Open to male participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-04-16.
Sponsored by Stealth BioTherapeutics Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A randomized, double-blind cross over trial to evaluate the safety, efficacy, and tolerability of elamipretide in subjects with Barth syndrome.
A phase 2 randomized, double-blind, placebo-controlled crossover trial to evaluate the safety, tolerability, and efficacy of subcutaneous injections of elamipretide in subjects with genetically confirmed Barth syndrome followed by open-label treatment extension. Part 1 was a randomized, double-blind, placebo-controlled, crossover trial to assess safety, tolerability, and efficacy single daily subcutaneous (SC) doses of 40 mg elamipretide administered for 12 weeks in subjects with Barth syndrome. Part 2: This was an open-label extension trial to assess the long-term safety, tolerability, and longitudinal trends in efficacy single daily SC doses of 40 mg elamipretide for up to 192 weeks.
Stealth BioTherapeutics Inc. is the lead sponsor of 30 studies on the registry; 3 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At the screening visit, must meet the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Experimental Part 1: 12 weeks of single daily SC doses of 40 mg elamipretide in Treatment Period 1 followed by 12 weeks of treatment with placebo in Treatment Period 2 (separated by a 4 week washout period). Experimental Open Label Extension Part 2: All subjects will receive Elamipretide 40mg SC daily injections for up to 168 weeks
Drug: Elamipretide · Drug: Placebo
Placebo Comparator Part 1: 12 weeks of single daily SC doses of placebo in Treatment Period 1 followed by 12 weeks of treatment with 40 mg elamipretide in Treatment Period 2 (separated by a 4 week washout period). Placebo Comparator Open Label Extension Part 2: All subjects will receive Elamipretide 40mg SC daily injections for up to 168 weeks
Drug: Elamipretide · Drug: Placebo
40 mg daily subcutaneous injection for 12 weeks
Also known as: MTP-131
daily subcutaneous injection for 12 weeks
Also known as: Placebo Comparator
Part 1: Distance Walked During the 6-Minute Walk Test (6MWT) by Visit
Average distance walked in meters during the 6-minute walk test (6MWT) at end of treatment, where end of treatment means end of Visit 5 (Week 12) for Period 1 and end of Visit 10 (Week 12) for Period 2. Results were pooled for each 12 week period.
Time frame: Pre-dose to Week 12 (end of treatment)
Part 1: Total Fatigue Score Based on the BTHS-SA by Visit.
Total Fatigue Score (Q1, Q2, and Q4) Based on the BarTH Syndrome Symptom Assessment (BTHS-SA) by visit at predose, Weeks 1, 4, 8, and 12 (end of treatment). The BTHS-SA is 3-question fatigue assessment using a 0 to 4-point scale for each question where no fatigue =0 and very severe fatigue =4, with scores from all 3 questions combined and averaged for all subjects; a lower score means better outcome, higher score means a worse outcome. Combined Min score=0, max score =12. Weekly values are based on the weekly average of the last 7 days before the site or visiting nurse visit for both periods. Results from each 12-week period were combined, where end of treatment for Period 1 =Visit 5 (week 12), and End of Period 2 = Visit 10 (week 12)
Time frame: Pre-dose, Weeks 1, 4, 8, and 12 (end of treatment)
Part 2: Distance Walked During the 6MWT
Change from baseline for distance walked in meters during the 6-minute walk test (6MWT) by visit where Baseline= Part 1 Period 1 Pre-dose
Time frame: Baseline to Weeks 12, 24, 36, 48, 72, 96, 168, 192
Part 2: Change From Baseline: Total Fatigue Score (Q1, Q2, and Q4) Based on the BTHS-SA by Visit
Change from Baseline (mean) in Total Fatigue Score (Q1, Q2, and Q4) Based on the BarTH Syndrome Symptom Assessment (BTHS-SA) by visit. The BTHS-SA is 3-question fatigue assessment using a 0-4 point scale for each question where no fatigue =0 and very severe fatigue =4, with scores from all 3 questions combined and averaged for all subjects by visit; a lower score means better outcome, higher score means a worse outcome. Change from baseline: an increase in scores would mean worse outcome, a decrease in scores means better outcome. Combined Min score=-12, max score =12. Weekly values are based on the weekly average of the last 7 days before the site or visiting nurse visit for both periods. Baseline= Period 1 Predose.
Time frame: Baseline to Weeks 12, 24, 36, 48, 72, 96, 120, 144, 168, 192
Part 1: Muscle Strength as Measured by HHD by Visit
Muscle strength as measured by handheld dynamometry (HHD) in Newtons, where end of treatment means end of Visit 5 (Week 12) for Period 1 and end of Visit 10 (Week 12) for Period 2. Results were pooled for each 12 week period. Handheld dynamometry assesses the average strength of the knee extensors of both legs.
Time frame: Pre-dose to Week 12 (end of treatment)
Part 2: Change From Baseline: Muscle Strength by HHD (Newtons) by Visit
Muscle strength as measured by handheld dynamometry (HHD) in Newtons. Handheld dynamometry assesses the average strength of the knee extensors of both legs. Change from baseline where Baseline= Part 1 Period 1 Pre-dose: the greater positive change, the better the outcome, the smaller positive change (or negative change) the number the worse the outcome.
Time frame: Baseline to Weeks 12, 24, 36, 48, 72, 96,168, 192
Part 1: 5XSST by Visit
Time (in seconds) to complete the Five Times Sit-To-Stand, where end of treatment means end of Visit 5 (Week 12) for Period 1 and end of Visit 10 (Week 12) for Period 2. Results were pooled for each 12 week period.
Time frame: Pre-dose to Week 12 (end of treatment)
Part 2: Change From Baseline: 5X Sit to Stand by Visit
Change in baseline in time (in seconds), where Baseline= Part 1 Period 1 Pre-dose to complete the Five Times Sit-To-Stand by visit. More time means worse outcome, less time means better outcome.
Time frame: Baseline to Weeks 12, 24, 36, 48, 72, 96, 168, 192
Part 1: SWAY Application Balance Assessments by Visit
SWAY application balance assessment consists of five stances each performed for 10 seconds and scores postural stability on a scale from 0-100 with higher scores indicating better postural stability from Pre-dose to Week 12 (end of treatment), where end of treatment means end of Visit 5 (Week 12) for Period 1 and end of Visit 10 (Week 12) for Period 2. Results were pooled for each 12 week period.
Time frame: Pre-dose to Week 12 (end of treatment)
Part 2: Change From Baseline: SWAY Application Balance Assessment
Change from Baseline: SWAY Application Balance Assessment,where Baseline= Part 1 Period 1 Pre-doseSWAY application balance assessment consists of five stances each performed for 10 seconds and scores postural stability on a scale from 0-100 with higher scores indicating better postural stability. An increase from baseline is a better outcome and a decrease in score is a worse outcome.
Time frame: Baseline to Weeks 12, 24, 36, 48, 72, 96,168, 192
Part 1: Patient Global Impression Scales of Symptoms
Patient-reported health status over the past week, by visit, where end of treatment means end of Visit 5 (Week 12) for Period 1 and end of Visit 10 (Week 12) for Period 2. Results were pooled for each 12 week period. Scores range from 0-40 for adolescents and 0-50 for adults. PGI Scale is as follows: 0=None, 1=Mild, 2=Moderate, 3=Severe, and 4=Very Severe. Higher score means worse health status, means worse outcome; lower score means better health status, means better outcome.
Time frame: Pre-dose, Week 1, Week 12 (end of treatment)
Part 2: Change From Baseline: Patient Global Impression Scales of Symptoms by Visit
Part 2: Change from Baseline: Patient Global Impression Scales of Symptoms by Visit Patient-reported health status over the past week where Baseline= Part 1 Period 1 Pre-dose, administered at Week 12 for Period 1 and Period 2. Scores range from 0-40 for adolescents and 0-50 for adults. PGI Scale is as follows: 1=None, 2=Mild, 3=Moderate, 4=Severe, and 5=Very Severe. Change from baseline: Higher score means worse health status, means worse outcome; lower score means better health status, means better outcome.
Time frame: Baseline to Weeks 12, 24, 36, 48, 72, 96, 120, 144, 168, 192
Part 1: Part 1: Clinician Global Impression
Clinician Global Impression Scale by visit: Clinician-reported overall health status at end of treatment, administered at Week 12 for Period 1 and Period 2. Scores range from 0-6 for both adolescents and adults. PGI Scale is as follows: 1= Very much Better, 2= Moderately Better, 3= A Little Better, 4= No Change, and 5= A Little Worse 6= Very much Worse. Higher score means worse health status, means worse outcome; lower score means better health status, means better outcome. End of treatment means end of Visit 5 (Week 12) for Period 1 and end of Visit 10 (Week 12) for Period 2. Results were pooled for each 12 week period.
Time frame: Pre-dose to Week 12 (end of treatment)
Part 2: Change From Baseline: CGI Symptom Scale
Change from Baseline: CGI Symptom Scale by visit where Baseline= Part 1 Period 1 Pre-dose. Clinician Global Impression Scale: Clinician-reported overall health status at end of treatment, administered at Week 12 for Period 1 and Period 2. Scores range from 0-6 for both adolescents and adults. PGI Scale is as follows: 1= Very much Better, 2= Moderately Better, 3= A Little Better, 4= No Change, and 5= A Little Worse 6= Very much Worse. Change from baseline: higher score means worse health status, means worse outcome; lower score means better health status, means better outcome.
Time frame: Baseline to Weeks 12, 24, 36, 48, 72, 96, 120, 144, 168, 192
| Milestone | Experimental: Elamipretide, Then Placebo | Placebo, Then Elamipretide |
|---|---|---|
| Started | 6 | 6 |
| Completed | 6 | 6 |
| Not completed | 0 | 0 |
| Milestone | Experimental: Elamipretide, Then Placebo | Placebo, Then Elamipretide |
|---|---|---|
| Started | 6 | 6 |
| Completed | 6 | 6 |
| Not completed | 0 | 0 |
| Milestone | Experimental: Elamipretide, Then Placebo | Placebo, Then Elamipretide |
|---|---|---|
| Started | 6 | 6 |
| Completed | 6 | 6 |
| Not completed | 0 | 0 |
| Milestone | Experimental: Elamipretide, Then Placebo | Placebo, Then Elamipretide |
|---|---|---|
| Started | 5 | 5 |
| Week 12 | 5 | 5 |
| Week 36 | 3 | 5 |
| Week 168 | 3 | 5 |
| Completed | 3 | 5 |
| Not completed | 2 | 0 |
| Withdrew: Adverse event | 2 | 0 |
Average distance walked in meters during the 6-minute walk test (6MWT) at end of treatment, where end of treatment means end of Visit 5 (Week 12) for Period 1 and end of Visit 10 (Week 12) for Period 2. Results were pooled for each 12 week period.
| meters | Experimental: Elamipretide | Placebo |
|---|---|---|
| Pre-dose | 400.1 ± 55.07 | 412.6 ± 60.16 |
| Week 12 (End of Treatment | 443.1 ± 65.43 | 443.9 ± 77.10 |
Total Fatigue Score (Q1, Q2, and Q4) Based on the BarTH Syndrome Symptom Assessment (BTHS-SA) by visit at predose, Weeks 1, 4, 8, and 12 (end of treatment). The BTHS-SA is 3-question fatigue assessment using a 0 to 4-point scale for each question where no fatigue =0 and very severe fatigue =4, with scores from all 3 questions combined and averaged for all subjects; a lower score means better outcome, higher score means a worse outcome. Combined Min score=0, max score =12. Weekly values are based on the weekly average of the last 7 days before the site or visiting nurse visit for both periods. Results from each 12-week period were combined, where end of treatment for Period 1 =Visit 5 (week 12), and End of Period 2 = Visit 10 (week 12)
| score on a scale | Experimental: Elamipretide | Placebo |
|---|---|---|
| Pre-dose | 7.672 ± 1.9360 | 7.433 ± 1.3848 |
| Week 1 | 6.837 ± 2.1114 | 6.994 ± 1.7093 |
| Week 4 | 6.220 ± 2.3325 | 6.485 ± 1.4447 |
| Week 8 | 6.089 ± 1.8344 | 6.196 ± 1.7815 |
| Week 12 | 6.305 ± 2.0612 | 6.240 ± 1.6384 |
Change from baseline for distance walked in meters during the 6-minute walk test (6MWT) by visit where Baseline= Part 1 Period 1 Pre-dose
| meters | Part 1: Elamipretide (Sequence AB) | Part 2: Placebo (Sequence BA) |
|---|---|---|
| Part 2: Week 12 | 45.4 ± 55.73 | 75.6 ± 87.25 |
| Part 2: Week 24 | 79.8 ± 23.54 | 100.4 ± 94.61 |
| Part 2: Week 36 | 68.0 ± 31.19 | 112.6 ± 119.35 |
| Part 2: Week 48 | 87.3 ± 25.58 | 103.4 ± 102.02 |
| Part 2: Week 72 | 121.7 ± 20.74 | 97.8 ± 117.53 |
| Part 2: Week 96 | 128.0 | 63.7 ± 69.14 |
| Part 2: Week 168 | 89.3 ± 32.75 | 100.2 ± 78.10 |
| Part 2: Week 192 | 118.0 | 125.0 ± 28.28 |
Change from Baseline (mean) in Total Fatigue Score (Q1, Q2, and Q4) Based on the BarTH Syndrome Symptom Assessment (BTHS-SA) by visit. The BTHS-SA is 3-question fatigue assessment using a 0-4 point scale for each question where no fatigue =0 and very severe fatigue =4, with scores from all 3 questions combined and averaged for all subjects by visit; a lower score means better outcome, higher score means a worse outcome. Change from baseline: an increase in scores would mean worse outcome, a decrease in scores means better outcome. Combined Min score=-12, max score =12. Weekly values are based on the weekly average of the last 7 days before the site or visiting nurse visit for both periods. Baseline= Period 1 Predose.
| score on a scale | Part 2: OLE: (Treatment AB) | Part 2: OLE: (Treatment BA) |
|---|---|---|
| Baseline | -2.425 ± 2.0849 | -1.540 ± 1.3653 |
| Week 12 | -1.800 ± 2.4838 | -1.314 ± 1.4237 |
| Week 24 | -1.500 ± 2.0253 | -0.314 ± 1.0816 |
| Week 36 | -2.667 ± 3.6821 | -1.714 ± 1.0583 |
| Week 48 | -1.000 ± 2.9172 | -0.314 ± 1.0650 |
| Week 72 | -2.667 ± 3.4827 | -1.114 ± 1.1301 |
| Week 96 | -3.500 ± 2.5254 | -0.357 ± 1.5763 |
| Week 120 | -3.000 ± 2.9172 | -0.114 ± 1.0309 |
| Week 144 | -2.667 ± 2.2961 | -0.314 ± 2.0067 |
| Week 168 | -2.333 ± 4.0515 | -0.514 ± 0.7309 |
| Week 192 | -5.286 | -1.107 ± 0.5556 |
Muscle strength as measured by handheld dynamometry (HHD) in Newtons, where end of treatment means end of Visit 5 (Week 12) for Period 1 and end of Visit 10 (Week 12) for Period 2. Results were pooled for each 12 week period. Handheld dynamometry assesses the average strength of the knee extensors of both legs.
| Newtons | Experimental: Elamipretide | Placebo |
|---|---|---|
| Pre-dose | 131.236 ± 29.9004 | 123.100 ± 24.6762 |
| Week 12 | 135.934 ± 52.2796 | 129.253 ± 34.2395 |
Muscle strength as measured by handheld dynamometry (HHD) in Newtons. Handheld dynamometry assesses the average strength of the knee extensors of both legs. Change from baseline where Baseline= Part 1 Period 1 Pre-dose: the greater positive change, the better the outcome, the smaller positive change (or negative change) the number the worse the outcome.
| Newtons | Part 2: OLE: (Treatment AB) | Part 2: OLE: (Treatment BA) |
|---|---|---|
| Week 12 | 33.606 ± 24.7304 | 42.147 ± 34.9498 |
| Week 24 | 54.073 ± 29.7699 | 54.068 ± 37.3060 |
| Week 36 | 68.798 ± 22.8892 | 48.351 ± 31.1331 |
| Week 48 | 69.613 ± 20.8788 | 45.704 ± 56.8895 |
| Week 72 | 62.089 ± 33.4753 | 32.071 ± 31.7087 |
| Week 96 | 93.745 | 38.848 ± 18.1422 |
| Week 168 | 57.751 ± 17.7509 | 61.897 ± 19.1573 |
| Week 192 | 42.368 | 32.140 ± 17.9287 |
Time (in seconds) to complete the Five Times Sit-To-Stand, where end of treatment means end of Visit 5 (Week 12) for Period 1 and end of Visit 10 (Week 12) for Period 2. Results were pooled for each 12 week period.
| seconds | Experimental: Elamipretide | Placebo |
|---|---|---|
| Pre-dose | 12.965 ± 3.3366 | 13.710 ± 5.3088 |
| Week 12 | 14.023 ± 5.4508 | 13.749 ± 6.1024 |
Change in baseline in time (in seconds), where Baseline= Part 1 Period 1 Pre-dose to complete the Five Times Sit-To-Stand by visit. More time means worse outcome, less time means better outcome.
| seconds | Part 2: OLE: (Sequence AB) | Part 2: OLE: (Sequence BA) |
|---|---|---|
| End of Part 1 | -0.773 ± 2.5323 | 0.400 ± 2.7824 |
| Week 12 | -1.505 ± 2.1843 | 0.384 ± 3.7167 |
| Week 24 | -2.533 ± 2.7507 | -1.160 ± 2.8668 |
| Week 36 | -3.700 ± 3.7649 | -0.344 ± 2.7035 |
| Week 48 | -4.780 ± 2.9820 | -0.082 ± 2.6625 |
| Week 72 | -4.770 ± 3.2043 | -0.454 ± 1.6369 |
| Week 96 | -8.060 | -0.397 ± 3.6036 |
| Week 168 | -4.320 ± 4.0307 | -0.986 ± 2.1857 |
| Week 192 | -6.850 | -0.390 ± 1.5839 |
SWAY application balance assessment consists of five stances each performed for 10 seconds and scores postural stability on a scale from 0-100 with higher scores indicating better postural stability from Pre-dose to Week 12 (end of treatment), where end of treatment means end of Visit 5 (Week 12) for Period 1 and end of Visit 10 (Week 12) for Period 2. Results were pooled for each 12 week period.
| Score on a scale | Experimental: Elamipretide | Placebo |
|---|---|---|
| Pre-dose | 70.752 ± 19.7199 | 68.820 ± 24.7478 |
| Week 12 | 78.698 ± 15.1554 | 71.353 ± 20.2515 |
Change from Baseline: SWAY Application Balance Assessment,where Baseline= Part 1 Period 1 Pre-doseSWAY application balance assessment consists of five stances each performed for 10 seconds and scores postural stability on a scale from 0-100 with higher scores indicating better postural stability. An increase from baseline is a better outcome and a decrease in score is a worse outcome.
| score on a scale | Part 2: OLE: (Sequence AB) | Part 2: OLE: (Sequence BA) |
|---|---|---|
| Week 12 | -3.152 ± 29.8419 | 10.464 ± 19.1971 |
| Week 24 | 12.190 ± 9.6799 | 6.664 ± 9.5896 |
| Week 36 | 0.807 ± 14.9493 | 9.484 ± 11.3834 |
| Week 48 | 5.773 ± 7.8814 | 15.260 ± 16.2540 |
| Week 72 | 10.420 ± 1.7501 | 15.240 ± 14.3557 |
| Week 96 | 12.840 | 18.433 ± 21.3323 |
| Week 168 | 21.127 ± 14.1854 | 19.644 ± 18.6821 |
| Week 192 | 15.100 | 13.080 ± 16.3483 |
Patient-reported health status over the past week, by visit, where end of treatment means end of Visit 5 (Week 12) for Period 1 and end of Visit 10 (Week 12) for Period 2. Results were pooled for each 12 week period. Scores range from 0-40 for adolescents and 0-50 for adults. PGI Scale is as follows: 0=None, 1=Mild, 2=Moderate, 3=Severe, and 4=Very Severe. Higher score means worse health status, means worse outcome; lower score means better health status, means better outcome.
| Score on a scale | Experimental: Elamipretide | Placebo |
|---|---|---|
| Predose | 1.7 ± 0.65 | 1.8 ± 0.83 |
| Week 1 | 1.7 ± 0.89 | 1.5 ± 1.00 |
| Week 12 | 1.4 ± 0.79 | 1.6 ± 0.67 |
Part 2: Change from Baseline: Patient Global Impression Scales of Symptoms by Visit Patient-reported health status over the past week where Baseline= Part 1 Period 1 Pre-dose, administered at Week 12 for Period 1 and Period 2. Scores range from 0-40 for adolescents and 0-50 for adults. PGI Scale is as follows: 1=None, 2=Mild, 3=Moderate, 4=Severe, and 5=Very Severe. Change from baseline: Higher score means worse health status, means worse outcome; lower score means better health status, means better outcome.
| score on a scale | Part 2: OLE: (Sequence AB) | Part 2: OLE: (Sequence BA) |
|---|---|---|
| End of Part 1 | 0.0 ± 0.00 | -0.4 ± 0.55 |
| Week 12 | -0.2 ± 1.10 | -0.6 ± 0.55 |
| Week 24 | -0.3 ± 0.50 | -0.4 ± 0.55 |
| Week 36 | -0.7 ± 1.15 | -0.6 ± 0.55 |
| Week 48 | -0.7 ± 1.15 | 0.0 ± 0.00 |
| Week 72 | -0.7 ± 1.15 | -0.4 ± 0.55 |
| Week 96 | -0.5 ± 2.12 | -0.3 ± 0.58 |
| Week 120 | -0.7 ± 1.15 | -0.6 ± 0.55 |
| Week 144 | -1.0 ± 1.41 | -0.8 ± 0.45 |
| Week 168 | -0.7 ± 1.15 | -0.6 ± 0.55 |
| Week 192 | -2.0 | -0.5 ± 0.71 |
Clinician Global Impression Scale by visit: Clinician-reported overall health status at end of treatment, administered at Week 12 for Period 1 and Period 2. Scores range from 0-6 for both adolescents and adults. PGI Scale is as follows: 1= Very much Better, 2= Moderately Better, 3= A Little Better, 4= No Change, and 5= A Little Worse 6= Very much Worse. Higher score means worse health status, means worse outcome; lower score means better health status, means better outcome. End of treatment means end of Visit 5 (Week 12) for Period 1 and end of Visit 10 (Week 12) for Period 2. Results were pooled for each 12 week period.
| Score on a scale | Experimental: Elamipretide | Placebo |
|---|---|---|
| Predose | 1.8 ± 0.45 | 1.4 ± 0.51 |
| 12 weeks | 1.6 ± 0.51 | 1.6 ± 0.51 |
Change from Baseline: CGI Symptom Scale by visit where Baseline= Part 1 Period 1 Pre-dose. Clinician Global Impression Scale: Clinician-reported overall health status at end of treatment, administered at Week 12 for Period 1 and Period 2. Scores range from 0-6 for both adolescents and adults. PGI Scale is as follows: 1= Very much Better, 2= Moderately Better, 3= A Little Better, 4= No Change, and 5= A Little Worse 6= Very much Worse. Change from baseline: higher score means worse health status, means worse outcome; lower score means better health status, means better outcome.
| score on a scale | Part 2: OLE: (Sequence AB) | Part 2: OLE: (Sequence BA) |
|---|---|---|
| Week 12 | -0.4 ± 0.55 | 0.0 ± 0.00 |
| Week 24 | -1.3 ± 0.96 | -0.4 ± 0.55 |
| Week 36 | -1.3 ± 0.58 | -0.2 ± 0.84 |
| Week 48 | -1.3 ± 0.58 | -0.4 ± 0.55 |
| Week 72 | -1.3 ± 0.58 | -0.6 ± 0.55 |
| Week 96 | -1.0 ± 0.00 | -0.7 ± 0.58 |
| Week 120 | -1.7 ± 0.58 | -1.0 ± 0.71 |
| Week 144 | -1.3 ± 0.58 | -0.6 ± 0.55 |
| Week 168 | -1.3 ± 0.58 | -0.8 ± 0.84 |
| Week 192 | -1.0 | -1.5 ± 0.71 |
Collected over Part 1: Participants were followed for a total of 28 weeks, they had a treatment period for 12 weeks, a washout period of 4 weeks, then another treatment period of 4 weeks. Part 2 OLE: Participants who agreed to proceed to Part 2 were followed for up to 192 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 2 (OLE): Elamipretide (Sequence AB) | 0/5 (0%) | 1/5 (20%) | 5/5 (100%) |
| Part 2 (OLE): Elamipretide (Sequence BA) | 0/5 (0%) | 4/5 (80%) | 5/5 (100%) |
| Part 1: Elamipretide | 0/6 (0%) | 0/12 (0%) | 12/12 (100%) |
| Part 1: Placebo | 0/6 (0%) | 0/12 (0%) | 12/12 (100%) |
| Event | Part 2 (OLE): Elamipretide (Sequence AB) | Part 2 (OLE): Elamipretide (Sequence BA) | Part 1: Elamipretide | Part 1: Placebo |
|---|---|---|---|---|
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/5 | 1/5 | 0/12 | 0/12 |
| MucositisGeneral disorders | 0/5 | 1/5 | 0/12 | 0/12 |
| CostochondritisMusculoskeletal and connective tissue disorders | 0/5 | 1/5 | 0/12 | 0/12 |
| Abscess of Right AxillaInfections and infestations | 0/5 | 1/5 | 0/12 | 0/12 |
| GastroenteritisInfections and infestations | 1/5 | 0/5 | 0/12 | 0/12 |
| Event | Part 2 (OLE): Elamipretide (Sequence AB) | Part 2 (OLE): Elamipretide (Sequence BA) | Part 1: Elamipretide | Part 1: Placebo |
|---|---|---|---|---|
| Injection site erythemaGeneral disorders | 3/5 | 5/5 | 12/12 | 3/12 |
| Injection site pruritusGeneral disorders | 3/5 | 5/5 | 8/12 | 2/12 |
| DizzinessNervous system disorders | 5/5 | 1/5 | 1/12 | 1/12 |
| Injection site painGeneral disorders | 3/5 | 4/5 | 9/12 | 4/12 |
| Injection site indurationGeneral disorders | 2/5 | 3/5 | 8/12 | 2/12 |
| Injection site urticariaGeneral disorders | 2/5 | 0/5 | 3/12 | 0/12 |
| HeadacheNervous system disorders | 2/5 | 1/5 | 1/12 | 3/12 |
| Weight decreasedInvestigations | 0/5 | 2/5 | 0/12 | 0/12 |
| Ear infectionInfections and infestations | 0/5 | 2/5 | 0/12 | 0/12 |
| Gastroenteritis viralInfections and infestations | 0/5 | 2/5 | 0/12 | 0/12 |
| Age, Continuous(years) | Experimental: Elamipretide (Treatment AB) | Experimental Placebo (Treatment BA) | Total |
|---|---|---|---|
| Part 1 | 23.3 ± 9.07 | 15.7 ± 3.33 | 19.5 ± 7.65 |
| PART 2: OLE | 21.8 ± 9.23 | 16.2 ± 3.42 | 19.0 ± 7.20 |
| Sex: Female, Male(Participants) | Experimental: Elamipretide (Treatment AB) | Experimental Placebo (Treatment BA) | Total |
|---|---|---|---|
| Part 1 — Female | 0 | 0 | 0 |
| Part 1 — Male | 6 | 6 | 12 |
| Part 2 (OLE) — Female | 0 | 0 | 0 |
| Part 2 (OLE) — Male | 5 | 5 | 10 |
| Race (NIH/OMB)(Participants) | Experimental: Elamipretide (Treatment AB) | Experimental Placebo (Treatment BA) | Total |
|---|---|---|---|
| Part 1 — American Indian or Alaska Native | 0 | 0 | 0 |
| Part 1 — Asian | 0 | 0 | 0 |
| Part 1 — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Part 1 — Black or African American | 0 | 0 | 0 |
| Part 1 — White | 6 | 5 | 11 |
| Part 1 — More than one race | 0 | 1 | 1 |
| Part 1 — Unknown or Not Reported | 0 | 0 | 0 |
| Part 2 (OLE) — American Indian or Alaska Native | 0 | 0 | 0 |
| Part 2 (OLE) — Asian | 0 | 0 | 0 |
| Part 2 (OLE) — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Part 2 (OLE) — Black or African American | 0 | 0 | 0 |
| Part 2 (OLE) — White | 5 | 4 | 9 |
| Part 2 (OLE) — More than one race | 0 | 1 | 1 |
| Part 2 (OLE) — Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Experimental: Elamipretide (Treatment AB) | Experimental Placebo (Treatment BA) | Total |
|---|---|---|---|
| United States | 6 | 6 | 12 |
| Body Mass Index(kg/m^2) | Experimental: Elamipretide (Treatment AB) | Experimental Placebo (Treatment BA) | Total |
|---|---|---|---|
| Part 1 | 18.23 ± 3.677 | 16.88 ± 4.179 | 17.56 ± 3.818 |
| Part 2 OLE | 18.14 ± 4.103 | 17.54 ± 4.313 | 17.84 ± 3.981 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2017 to primary completion in Oct 2018, 15 months.
Results were first posted in Apr 2024, 5 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elamipretide
Barth Syndrome
Stealth BioTherapeutics Inc. →